RU2017134796A - Органические соединения - Google Patents
Органические соединения Download PDFInfo
- Publication number
- RU2017134796A RU2017134796A RU2017134796A RU2017134796A RU2017134796A RU 2017134796 A RU2017134796 A RU 2017134796A RU 2017134796 A RU2017134796 A RU 2017134796A RU 2017134796 A RU2017134796 A RU 2017134796A RU 2017134796 A RU2017134796 A RU 2017134796A
- Authority
- RU
- Russia
- Prior art keywords
- disease
- disorder
- free
- salt form
- sert
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 7
- 150000003839 salts Chemical group 0.000 claims 7
- 102100028874 Sodium-dependent serotonin transporter Human genes 0.000 claims 6
- 101710114597 Sodium-dependent serotonin transporter Proteins 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000019901 Anxiety disease Diseases 0.000 claims 5
- 230000036506 anxiety Effects 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 230000001457 vasomotor Effects 0.000 claims 5
- 208000033830 Hot Flashes Diseases 0.000 claims 4
- 206010060800 Hot flush Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010013954 Dysphoria Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims 2
- 208000025569 Tobacco Use disease Diseases 0.000 claims 2
- 201000007930 alcohol dependence Diseases 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000030135 gastric motility Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000022925 sleep disturbance Diseases 0.000 claims 2
- 201000009032 substance abuse Diseases 0.000 claims 2
- 208000027559 Appetite disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 claims 1
- 102100033929 Sodium-dependent noradrenaline transporter Human genes 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 238000011010 flushing procedure Methods 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562135915P | 2015-03-20 | 2015-03-20 | |
| US62/135,915 | 2015-03-20 | ||
| PCT/US2016/023198 WO2016154027A1 (en) | 2015-03-20 | 2016-03-18 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2017134796A true RU2017134796A (ru) | 2019-04-04 |
Family
ID=56977765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017134796A RU2017134796A (ru) | 2015-03-20 | 2016-03-18 | Органические соединения |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10188758B2 (enExample) |
| EP (1) | EP3270920B1 (enExample) |
| JP (1) | JP6726200B2 (enExample) |
| KR (1) | KR20170129906A (enExample) |
| CN (1) | CN107405339A (enExample) |
| AU (1) | AU2016235483A1 (enExample) |
| BR (1) | BR112017020135A2 (enExample) |
| CA (1) | CA2978668A1 (enExample) |
| ES (1) | ES2819833T3 (enExample) |
| IL (1) | IL254320A0 (enExample) |
| MX (1) | MX2017012022A (enExample) |
| RU (1) | RU2017134796A (enExample) |
| WO (1) | WO2016154027A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3339304A1 (en) | 2016-12-20 | 2018-06-27 | Laboratorios del Dr. Esteve, S.A. | Quinoline and isoquinoline derivatives for treating pain and pain related conditions |
| EP3339307A1 (en) * | 2016-12-20 | 2018-06-27 | Laboratorios del Dr. Esteve, S.A. | Nitrogen containing bicyclic derivatives for treating pain and pain related conditions |
| CN113195489A (zh) * | 2018-11-02 | 2021-07-30 | 埃斯特韦制药股份公司 | 用于治疗疼痛和疼痛相关病症的新的烷氧基氨基吡啶衍生物 |
| EP3873902A1 (en) * | 2018-11-02 | 2021-09-08 | Esteve Pharmaceuticals, S.A. | New tetrahydropyrimidodiazepin and tetrahydropyridodiazepin compounds for treating pain and pain related conditions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU709704B2 (en) * | 1995-07-24 | 1999-09-02 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
| AU2003287023A1 (en) * | 2002-11-05 | 2004-06-03 | Eli Lilly And Company | 3-aryloxy/ thio-2, 3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake |
| EA200601798A1 (ru) * | 2004-04-30 | 2007-04-27 | Уорнер-Ламберт Компани Ллс | Замещенные соединения морфолина для лечения расстройств центральной нервной системы |
| WO2007010082A1 (en) * | 2005-07-15 | 2007-01-25 | Fermion Oy | Process for preparing a 3-aryloxy-3-arylpropylamine |
| CA2661187A1 (en) * | 2006-08-23 | 2008-02-28 | Pfizer Products Inc. | Piperidine derivatives |
| EP2161998B1 (en) * | 2007-06-04 | 2015-09-02 | Intra-Cellular Therapies, Inc. | Pyridine derivatives as NET/SERT modulators |
| WO2010120910A1 (en) * | 2009-04-15 | 2010-10-21 | Theravance, Inc. | 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds |
| US9352218B2 (en) | 2009-04-21 | 2016-05-31 | Nintendo Co., Ltd. | Game apparatus and computer-readable storage medium |
-
2016
- 2016-03-18 EP EP16769428.0A patent/EP3270920B1/en active Active
- 2016-03-18 WO PCT/US2016/023198 patent/WO2016154027A1/en not_active Ceased
- 2016-03-18 CA CA2978668A patent/CA2978668A1/en not_active Abandoned
- 2016-03-18 BR BR112017020135A patent/BR112017020135A2/pt not_active Application Discontinuation
- 2016-03-18 KR KR1020177030305A patent/KR20170129906A/ko not_active Withdrawn
- 2016-03-18 ES ES16769428T patent/ES2819833T3/es active Active
- 2016-03-18 AU AU2016235483A patent/AU2016235483A1/en not_active Abandoned
- 2016-03-18 JP JP2017549188A patent/JP6726200B2/ja active Active
- 2016-03-18 CN CN201680014968.7A patent/CN107405339A/zh active Pending
- 2016-03-18 RU RU2017134796A patent/RU2017134796A/ru not_active Application Discontinuation
- 2016-03-18 US US15/560,107 patent/US10188758B2/en active Active
- 2016-03-18 MX MX2017012022A patent/MX2017012022A/es unknown
-
2017
- 2017-09-04 IL IL254320A patent/IL254320A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL254320A0 (en) | 2017-11-30 |
| EP3270920B1 (en) | 2020-06-17 |
| BR112017020135A2 (pt) | 2018-05-29 |
| EP3270920A4 (en) | 2018-10-24 |
| KR20170129906A (ko) | 2017-11-27 |
| ES2819833T3 (es) | 2021-04-19 |
| US20180099060A1 (en) | 2018-04-12 |
| WO2016154027A1 (en) | 2016-09-29 |
| MX2017012022A (es) | 2018-01-30 |
| JP2018508556A (ja) | 2018-03-29 |
| US10188758B2 (en) | 2019-01-29 |
| CN107405339A (zh) | 2017-11-28 |
| AU2016235483A1 (en) | 2017-10-12 |
| CA2978668A1 (en) | 2016-09-29 |
| EP3270920A1 (en) | 2018-01-24 |
| JP6726200B2 (ja) | 2020-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2470011C2 (ru) | Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов | |
| RU2017134796A (ru) | Органические соединения | |
| RU2014145682A (ru) | Органические соединения | |
| CL2018000036A1 (es) | Derivados etinilo | |
| RU2019131111A (ru) | ПРОИЗВОДНОЕ ГЕТЕРОАРИЛ[4,3-с]ПИРИМИДИН-5-АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКИЕ ПРИМЕНЕНИЯ | |
| RU2007139541A (ru) | Производные хромана и хромена и их применение | |
| RU2018130727A (ru) | Органические соединения | |
| EA202090987A1 (ru) | Новые пролекарства на основе катехоламина для применения в лечении болезни паркинсона | |
| RU2003105900A (ru) | Производные 4,5-дигидро-1h-пиразола, обладающие cb1-антагонистической активностью | |
| TN2017000119A1 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| EA201791941A1 (ru) | Бициклические кетосульфонамидные соединения | |
| JP2005539068A5 (enExample) | ||
| JP2004518763A5 (enExample) | ||
| EA201590735A1 (ru) | 2-фенил-5-гетероциклил-тетрагидро-2h-пиран-3-аминовые соединения для применения в лечении диабета и связанных с ним расстройств | |
| EA201370184A1 (ru) | Гетероарильные производные | |
| RU2016131875A (ru) | Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы | |
| MA32943B1 (fr) | Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique | |
| CN111770754A (zh) | 一种多环类衍生物调节剂、其制备方法和应用 | |
| CY1109569T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης | |
| RU2008148941A (ru) | 4-[(3-фторфенокси)фенилметил]пиперидин метансульфонат, применение, способ синтеза и фармацевтические композиции | |
| JP2018508556A5 (enExample) | ||
| EA201892687A1 (ru) | Кристаллическая форма соединения, подавляющего активность протеинкиназы, и её применение | |
| WO2009148290A3 (en) | 3-substituted propanamine compounds | |
| RU2019102757A (ru) | Производные этинила | |
| FI3625213T3 (fi) | (+)-3-(2,3-Difluorifenyyli)-3-metoksipyrrolidiini-fumaraatti, menetelmä sen valmistamiseksi ja sen käytöt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20201005 |